Dextra Asia Co Ltd and Another v Mariwu Industrial Co (S) Pte Ltd [2007] SGHC 51

Case Details

• Citation: [2007] SGHC 51
• Court: High Court of the Republic of Singapore
• Decision Date: 12 April 2007
• Coram: Tan Lee Meng J
• Case Number: Suit 641/2004
• Hearing Date(s): [None recorded in extracted metadata]
• Claimants / Plaintiffs: Dextra Asia Co Ltd; Dextra Manufacturing Co Ltd
• Respondent / Defendant: Mariwu Industrial Co (S) Pte Ltd
• Counsel for Claimants: Daniel Lim and Cindy Quek (Shook Lin & Bok)
• Counsel for Respondent: Wong Siew Hong and Kalaiselvi Singaram (Infinitus Law Corporation)
• Practice Areas: Patents and Inventions; Novelty; Evidence; Civil Procedure
• Subject Matter: Alleged infringement of patent for manufacturing process; validity challenge based on prior use and prior disclosure.

Summary

The judgment in Dextra Asia Co Ltd and Another v Mariwu Industrial Co (S) Pte Ltd [2007] SGHC 51 serves as a definitive exploration of the evidentiary weight accorded to commercial "bluffs" in the context of patent validity challenges. The proceedings followed a remittal from the Court of Appeal, which had allowed the defendant, Mariwu Industrial Co (S) Pte Ltd ("Mariwu"), to introduce further evidence intended to prove that the "Bartec" patent—a process used for reinforcing concrete in construction—was invalid for lack of novelty. The plaintiffs, Dextra Asia Co Ltd and Dextra Manufacturing Co Ltd (collectively "Dextra"), had previously secured a judgment in 2006 finding that Mariwu had infringed the patent. Mariwu’s appeal rested on the discovery of 1994 correspondence and meeting minutes which allegedly contained admissions by Dextra and its associates that the Bartec process was already in the public domain in France and Hong Kong prior to its priority date.

The core of the dispute revolved around a high-stakes negotiation in late 1994 between Dextra, its licensor Etablissements A Mure ("Mure"), and another licensee, CCL Systems Limited ("CCL"). At the time, Dextra and CCL sought to reduce their royalty payments from 5% to a lower rate (eventually 2.5% or 2%) and to prevent Mure from selling the patent to a third party. To gain leverage, Dextra and CCL asserted in writing and during a meeting in Lyon that the patent was "not new" and had been "already used." Mariwu contended that these statements constituted formal admissions under the Evidence Act, effectively estopping Dextra from maintaining the patent's validity in the subsequent infringement suit.

Tan Lee Meng J was tasked with determining whether these historical assertions of prior use were factual admissions or merely strategic "gamesmanship." The court’s analysis required a granular examination of the motivations behind the 1994 communications. Dextra’s primary witness, Dr J M Pithon, testified that the claims of prior use were a "bluff" designed to "try their luck" in negotiations. The court also had to contend with the hearsay nature of internal memoranda produced by CCL, which Mariwu relied upon to suggest that the patent owner, Mure, had conceded the patent's invalidity during the Lyon meeting.

Ultimately, the High Court held that the further evidence did not establish the invalidity of the Bartec patent. The court found that the alleged admissions were commercial tactics rather than statements of objective fact. Furthermore, the court noted the commercial irrationality of Dextra and CCL continuing to pay millions in royalties for over a decade if they truly believed the patent was invalid. The judgment reinforces the principle that the burden of proving prior use remains on the party challenging the patent and cannot be discharged solely by pointing to uncorroborated, strategically motivated statements made in a non-legal, commercial setting. The decision affirms the 2006 finding of infringement and provides a robust framework for distinguishing between tactical negotiation and legal admissions of fact.

Timeline of Events

1. 3 November 1994: A pivotal meeting was held in Lyon, France ("the Lyon meeting"), attended by representatives of Mure (the patent owner), Dextra (the licensee), and CCL (another licensee). The parties discussed royalty rates and the potential sale of the Bartec patent.
2. 23 November 1994: Dextra and CCL sent a joint letter to Mure asserting that the Bartec patent was "not new" and was "already used in France and Hong Kong" prior to its registration. This was part of a strategy to negotiate lower royalties.
3. 12 December 1994: Internal correspondence and further communications between the parties continued regarding the validity of the patent and the proposed royalty reductions.
4. 13 December 1994: Dextra and CCL maintained their pressure on Mure, suggesting that the patent's lack of novelty would make it difficult to defend against competitors.
5. 14 December 1994: The period of intense negotiation culminated in further correspondence where the licensees sought to reduce the royalty rate from 5% to 2.5% or 2%.
6. 23 November 2004: The legal proceedings in Suit 641/2004 were underway, leading toward the initial trial on infringement and validity.
7. 2006: The High Court delivered its first judgment in Dextra Asia Co Ltd and Anor v Mariwu Industrial Co (S) Pte Ltd [2006] 2 SLR 154, finding that Mariwu had infringed the Bartec patent and that the patent was valid.
8. Post-2006: Mariwu appealed the first judgment and applied to the Court of Appeal to admit further evidence regarding the 1994 negotiations. The Court of Appeal allowed the application and remitted the matter to the trial judge.
9. 12 April 2007: Tan Lee Meng J delivered the judgment in [2007] SGHC 51, upholding the validity of the patent despite the new evidence.

What Were the Facts of This Case?

The plaintiffs, Dextra Asia Co Ltd and Dextra Manufacturing Co Ltd, were the holders of rights in Asia to a patented invention known as "Bartec." This process is a specialized method for reinforcing concrete, widely used in the construction of buildings and infrastructure. The patent was originally owned by a French entity, Etablissements A Mure ("Mure"). In the early 1990s, Dextra was a licensee of the Bartec patent, paying royalties to Mure at a rate of 5%. Another company, CCL Systems Limited ("CCL"), was also a licensee of the same patent, operating in different geographical markets.

The dispute originated when Dextra alleged that Mariwu Industrial Co (S) Pte Ltd had infringed the Bartec patent in Singapore. In the initial trial, the court found in favor of Dextra, ruling that the patent was valid and that Mariwu's activities constituted an infringement. Mariwu, however, sought to overturn this decision on appeal by introducing new evidence that had not been considered during the first trial. This evidence centered on the 1994 negotiations between Mure, Dextra, and CCL, which Mariwu claimed proved that the patent lacked novelty due to prior use in France and Hong Kong.

In 1994, Mure was considering selling the Bartec patent to a third party, which Dextra and CCL viewed as a significant threat to their commercial interests. To prevent the sale to a competitor and to negotiate a reduction in their own royalty obligations, Dextra and CCL joined forces. They adopted a strategy of attacking the validity of the very patent they were licensing. They claimed that the Bartec process was not novel because it had been used in France and Hong Kong before the patent's priority date. This culminated in the Lyon meeting on 3 November 1994, where Dr J M Pithon (representing Dextra) and Mr Robert J Copping (representing CCL) met with Mure's representatives.

Following the Lyon meeting, Dextra and CCL sent a letter dated 23 November 1994 to Mure, explicitly stating that the patent was "not new" and had been "already used in France and Hong Kong." They used this assertion to demand a reduction in the royalty rate from 5% to 2%. Mariwu contended that these statements were admissions of fact by the patent's own licensees and predecessors in title, which proved that the patent was invalid for lack of novelty. Mariwu’s counsel, Mr Wong Siew Hong, asserted that these were not mere "bluffs" but factual acknowledgments of the state of the art at the time.

The evidence record included an internal CCL memorandum summarizing the Lyon meeting, which suggested that Mure had acknowledged the prior use. However, during the remitted hearing, the witnesses gave a different account. Dr Pithon, Dextra’s main witness, testified that the claims of prior use were a "bluff" and "gamesmanship" intended to "try their luck" in forcing Mure to lower the royalties. He admitted that they had no concrete evidence of prior use at the time and were merely using the threat of invalidity as a bargaining chip. Mr Robert J Copping, who had been a director of CCL from 1991 to 1998, also testified. While his affidavit (AEIC) initially seemed to support Mariwu's case, his oral testimony revealed that he could not verify the truth of the prior use claims and that the strategy was indeed a commercial tactic.

The court also looked at the subsequent conduct of the parties. Despite their claims that the patent was invalid, Dextra continued to pay royalties to Mure, albeit at a reduced rate of 2.5% instead of the original 5%. The court noted that if Dextra truly believed the patent was invalid and could be easily overturned, it would have been commercially irrational to continue paying millions of dollars in royalties over the following decade. The central factual question was whether the 1994 statements were genuine admissions of a known lack of novelty or merely strategic lies told in a boardroom negotiation. Mariwu failed to produce any independent evidence—such as project records, technical drawings, or third-party testimonies from the 1990s—to support the claim that the Bartec process had actually been used in France or Hong Kong before the priority date.

What Were the Key Legal Issues?

The primary legal issue was whether the Bartec patent was invalid due to a lack of novelty, specifically through prior use in France and Hong Kong before the priority date. This required the court to evaluate whether the "further evidence" admitted by the Court of Appeal was sufficient to displace the findings of the first trial. The challenge to novelty was grounded in the assertion that the manufacturing process had been disclosed or used in a manner that made it part of the state of the art.

A secondary but critical issue was the admissibility and weight of the alleged admissions made by Dextra and CCL in 1994. This involved an interpretation of the Evidence Act (Cap 97, 1990 Ed), particularly section 18(3)(b), which deals with admissions made by persons from whom the parties to a suit have derived their interest. The court had to decide:

• Whether the statements made by Dextra and CCL in the 1994 correspondence and during the Lyon meeting constituted formal admissions that were binding or highly persuasive in the current litigation under section 18(3)(b) of the Evidence Act.
• Whether the "hearsay" nature of the internal CCL memorandum and the testimony of Mr Copping regarding Mure's alleged statements affected the reliability of the evidence regarding what was actually said at the Lyon meeting.
• Whether a "commercial bluff" could serve as a valid defense to an apparent admission of fact, and how the court should weigh such an explanation against written evidence.

The court also had to weigh the credibility of Dr Pithon and Mr Copping. The legal question was how to treat testimony that essentially admitted to prior dishonesty (the bluff) in order to maintain the current legal position (the validity of the patent). This required a careful balancing of the written record from 1994 against the oral testimony provided in 2007, and whether the defendant had met the high burden of proof required to invalidate a granted patent.

How Did the Court Analyse the Issues?

The court’s analysis began with a deep dive into the 1994 negotiations. Tan Lee Meng J examined the context of the Lyon meeting and the subsequent correspondence. He noted that the primary objective of Dextra and CCL was to prevent Mure from selling the Bartec patent to a competitor and to reduce their royalty burden. The court found that the assertions of prior use were strategically deployed to achieve these ends. Dr Pithon’s testimony was central to this finding; he stated that the licensees were "trying their luck" and that the claims were a "bluff." The court accepted this explanation, noting that in the "rough and tumble of the commercial world," parties often make assertions they cannot substantiate to gain leverage (at [11]).

The court was particularly struck by the commercial inconsistency of Mariwu's position. Tan Lee Meng J reasoned that if Dextra and CCL truly had evidence that the patent was invalid, they would not have agreed to continue paying royalties. The court observed:

"If the Bartec patent was as vulnerable as Mariwu now claims it was, it is difficult to understand why Dextra and CCL, who were then acting in concert, were prepared to continue paying royalties to Mure, even if the rate was reduced from 5% to 2.5%." (at [21])

The court then addressed the internal CCL memorandum, which Mariwu relied upon as evidence that Mure had admitted the patent's invalidity during the Lyon meeting. The court noted that this memorandum was hearsay. Citing Soon Peck Wah v Woon Che Chye [1998] 1 SLR 234, the court emphasized the rationale for the hearsay principle:

"The rationale for the hearsay principle is that the witness cannot verify the truth of the facts of which he has no personal knowledge." (at [27])

Mr Copping, who was present at the meeting, could not confirm that Mure had made any such admission. He clarified that while the licensees asserted the patent was invalid, Mure’s representatives did not concede the point in the way the memorandum suggested. The court found that the memorandum likely reflected the licensees' desired outcome or their own aggressive stance rather than a factual record of Mure's statements. The court further noted that Mr Copping’s AEIC, which seemed to support Mariwu, was undermined by his oral testimony where he admitted he had no personal knowledge of prior use in France or Hong Kong.

Regarding section 18(3)(b) of the Evidence Act, Mariwu argued that the statements made by Dextra in 1994 were admissions by a party from whom interest was derived. Section 18(3)(b) states that statements made by "persons from whom the parties to the suit have derived their interest in the subject matter of the suit, are admissions if made during the continuance of the interest of the persons making the statements." However, the court held that even if these statements were admissible as admissions, they were not conclusive. An admission can be explained away by showing the circumstances under which it was made. The court accepted Dr Pithon’s explanation that the statements were a "commercial bluff." The court noted that the fact that Dextra and CCL could not produce a single witness or document from 1994 that actually proved prior use in France or Hong Kong was fatal to Mariwu's case.

The court also scrutinized the specific claims regarding prior use in Hong Kong. Mariwu pointed to a letter where Dextra mentioned that the Bartec process was used in Hong Kong before the priority date. However, Dr Pithon explained that this was a reference to a different, non-patented process or a misunderstanding of the technical specifications. The court found that Mariwu failed to provide any independent evidence of what this "prior use" actually entailed. There were no project records, technical drawings, or third-party testimonies from the 1990s to support the claim. The court emphasized that the burden of proof for prior use is high and requires clear evidence of the specific process used.

Finally, the court addressed the technical aspects of the patent, specifically claims 4 and 5. It found that the "further evidence" did not touch upon the specific technical combinations that gave the Bartec process its novelty. The court concluded that the 1994 correspondence was too vague and strategically motivated to constitute the "clear and unmistakable" evidence required to invalidate a granted patent for lack of novelty. The court noted that the 1994 letters did not specify which elements of the Bartec process were allegedly old, making it impossible to conclude that the specific inventions in claims 4 and 5 were anticipated by prior art.

The court's analysis concluded that Mariwu had failed to bridge the gap between "tactical assertions" and "factual proof." The lack of any objective evidence of prior use, combined with the plausible explanation of the "bluff" and the subsequent conduct of the parties in paying royalties, led the court to maintain its original finding of validity. The court dismissed the idea that a party is forever bound by a statement made during a negotiation if that statement is later proven to be a tactical exaggeration.

What Was the Outcome?

The High Court ruled that the further evidence presented by Mariwu did not establish that the Bartec patent was invalid due to prior use. Consequently, the court saw no reason to alter the conclusion reached in the first judgment. The patent remained valid, and the finding of infringement against Mariwu stood. The court effectively dismissed the challenge to the patent's novelty, holding that the defendant had failed to discharge the burden of proof despite the admission of the 1994 documents.

The operative conclusion of the court was stated as follows:

"For reasons stated, I saw no reason for altering the conclusion in the first judgment that it was not established that the Bartec patent is invalid because of prior use, either in France or in Hong Kong." (at [32])

The result for the parties was that Dextra was confirmed as the holder of a valid patent and remained entitled to the damages previously awarded for Mariwu's infringement. For Mariwu, the attempt to use the 1994 "smoking gun" correspondence failed because the court looked past the literal text of the letters to the commercial reality of the situation. The court accepted that the "admissions" relied upon by Mariwu were neutralized by the "bluff" defense and the lack of corroborating objective evidence. No new orders as to costs were detailed in this specific judgment, as the primary focus was the determination of the remitted issue of novelty, which essentially affirmed the status quo of the 2006 decision.

The court's decision meant that the original orders from the first judgment, including the entitlement to damages for infringement, remained in full force. The dismissal of the novelty challenge based on the 1994 evidence closed the door on Mariwu's primary appellate strategy for revoking the patent. The judgment stands as a significant victory for Dextra, validating their patent rights against a sophisticated challenge based on their own prior commercial statements.

Why Does This Case Matter?

This case is of paramount importance to patent practitioners and commercial litigators because it clarifies the limits of using "admissions" made during commercial negotiations to invalidate intellectual property rights. It establishes that the court will not blindly accept written assertions of fact if they can be shown to be tactical "bluffs" or "gamesmanship" intended to achieve a specific business objective. This provides a necessary safeguard for companies that may engage in aggressive negotiation tactics, ensuring that such tactics do not inadvertently destroy their legal rights in a subsequent litigation context.

Furthermore, the judgment reinforces the high evidentiary threshold required to prove prior use. In Singapore, as in many other jurisdictions, a patent is presumed valid upon grant. To overturn this presumption based on prior use, a challenger must provide clear and unmistakable evidence of the specific technology or process that was in the public domain. The Dextra case demonstrates that even a "confession" of prior use by the patent holder's own licensee may be insufficient if it is uncorroborated by objective technical evidence and can be explained as a negotiation ploy.

The court’s treatment of section 18(3)(b) of the Evidence Act is also significant. It confirms that while statements by predecessors in title are admissible, they are not conclusive. This allows parties to "explain away" prior inconsistent statements by providing context, such as the pressure of a commercial negotiation or the lack of technical knowledge at the time the statement was made. This flexibility is crucial in complex commercial disputes where the history of a patent may span decades and involve multiple parties with varying interests.

The case also highlights the importance of subsequent conduct as an evidentiary tool. The court’s observation that Dextra continued to pay royalties despite its claims of invalidity is a classic application of the principle that "actions speak louder than words." For practitioners, this serves as a reminder that the court will look at the totality of the parties' behavior to determine the truth of a matter, rather than focusing solely on isolated documents.

Finally, the decision underscores the risks of hearsay evidence in patent trials. The rejection of the CCL memorandum because it was hearsay and could not be verified by the witnesses present at the meeting serves as a cautionary tale. It emphasizes the need for direct testimony from individuals with personal knowledge of the facts, especially when those facts are as critical as an alleged admission of patent invalidity by the patent owner.

Practice Pointers

• Caution in Negotiations: Practitioners should advise clients that while "bluffing" is a common negotiation tactic, any written assertions regarding the validity or novelty of a patent can be used against them in future litigation. Even if explainable, such statements create significant evidentiary hurdles.
• Corroborating Prior Use: When challenging a patent for lack of novelty, do not rely solely on admissions or correspondence. Seek objective evidence such as project records, invoices, technical drawings, or third-party witness testimony that can independently verify the prior use.
• Explaining Admissions: If a client has made a prior inconsistent statement, prepare to provide a detailed and plausible explanation of the circumstances (e.g., commercial pressure, tactical gamesmanship, or lack of information) to neutralize its weight under the Evidence Act.
• Hearsay Risks: Be wary of relying on internal memoranda or minutes of meetings prepared by third parties to prove admissions by an opponent. Without a witness who can verify the truth of the statements, such documents may be excluded or given minimal weight as hearsay.
• Conduct as Evidence: Use the parties' subsequent conduct (e.g., continued payment of royalties, licensing agreements) to support or undermine claims of patent invalidity. Commercial consistency is a powerful persuasive tool in the eyes of the court.
• Technical Specificity: Ensure that any evidence of prior use specifically addresses the claims of the patent in suit. Vague assertions of "prior use" of a general process are unlikely to invalidate specific technical claims (like claims 4 and 5 in this case).

Subsequent Treatment

The decision in Dextra Asia Co Ltd and Another v Mariwu Industrial Co (S) Pte Ltd [2007] SGHC 51 has been recognized for its practical approach to the "bluff" defense in commercial litigation. It is frequently cited in the context of patent novelty challenges to emphasize the high burden of proof required for prior use. The case’s interpretation of section 18(3)(b) of the Evidence Act remains a key reference point for how courts should weigh admissions made by predecessors in title. Later cases have followed its lead in distinguishing between tactical commercial statements and binding legal admissions, particularly where the statements are uncorroborated by objective facts.

Legislation Referenced

• Evidence Act (Cap 97, 1990 Rev Ed): Specifically section 18(3)(b), which governs admissions made by persons from whom the parties to the suit have derived their interest in the subject matter of the suit.

Cases Cited

• Soon Peck Wah v Woon Che Chye [1998] 1 SLR 234: Referred to at [27] regarding the rationale for the hearsay principle and the inability of a witness to verify facts of which they have no personal knowledge.
• Dextra Asia Co Ltd and Anor v Mariwu Industrial Co (S) Pte Ltd [2006] 2 SLR 154: The "first judgment" which initially found the patent valid and infringed.

Source Documents

• Original judgment PDF: Download (PDF, hosted on Legal Wires CDN)
• Official eLitigation record: View on elitigation.sg